ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...
Moderna Surprises the Street by Predicting a Bigger-Than-Expected Sales Drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...
Yahoo Finance24d
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Analysts expect, on average, $2.92 billion in revenue for 2025, according to FactSet. The company also ... approved a Moderna vaccine for RSV, or respiratory syncytial virus.
Newsweek24d
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
Weak adoption of Moderna’s respiratory syncytial virus (RSV ... according to the financial information company FactSet. Just a year ago, analysts anticipated $5 billion in 2025 revenue.
Morningstar24d
Moderna's stock tumbles to post-COVID lows after revenue outlook disappoints
while its mResvia vaccine for respiratory syncytial virus (RSV) contributed "minimal" sales. That compared with previous guidance of $3.0 billon to $3.5 billion, and is below the FactSet sales ...
clickondetroit.com24d
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Recommended Videos Analysts expect, on average, $2.92 billion in revenue for 2025, according to FactSet ... approved a Moderna vaccine for RSV, or respiratory syncytial virus.